» Articles » PMID: 17683483

A Rapid Oxidation and Persistent Decrease in the Vesicular Monoamine Transporter 2 After Methamphetamine

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2007 Aug 9
PMID 17683483
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Methamphetamine (METH) produces long-term decreases in markers of dopamine (DA) terminals in animals and humans. A decrease in the function of the vesicular monoamine transporter 2 (VMAT2) has been associated with damage to striatal DA terminals caused by METH; however, a possible mechanism for this decrease in VMAT2 function has not been defined. The current study showed that METH caused a rapid decrease to 68% of controls in VMAT2 protein immunoreactivity of the vesicular fraction from striatal synaptosomes within 1 h after a repeated high-dose administration regimen of METH. This decrease was associated with a 75% increase in nitrosylation of VMAT2 protein in the synaptosomal fraction as measured by nitrosocysteine immunoreactivity of VMAT2 protein. The rapid decreases in VMAT2 persisted when evaluated 7 days later and were illustrated by decreases in VMAT2 immunoreactivity and DA content of the vesicular fraction to 34% and 51% of control values, respectively. The decreases were blocked or attenuated by prior injections of the neuronal nitric oxide synthase inhibitor, S-methyl-l-thiocitrulline. These studies demonstrate that METH causes a rapid neuronal nitric oxide synthase-dependent oxidation of VMAT2 and long-term decreases in VMAT2 protein and function. The results also suggest that surviving DA terminals after METH exposure may have a compromised capacity to buffer cytosolic DA concentrations and DA-derived oxidative stress.

Citing Articles

Neurotoxicity mechanisms and clinical implications of six common recreational drugs.

Wang J, Hao Y, Ma D, Feng L, Yang F, An P Front Pharmacol. 2025; 16:1526270.

PMID: 40034818 PMC: 11873747. DOI: 10.3389/fphar.2025.1526270.


Exploring the Relationship Between VMAT2 and DAT Expression, Psychotic Experiences, Craving, and Treatment Motivation in Male Patients with Methamphetamine Use Disorder.

Keskinsezer M, Yazici A, Eskiler G, Hamarat K, Davutoglu O, Yazici E J Clin Med. 2024; 13(23).

PMID: 39685567 PMC: 11642686. DOI: 10.3390/jcm13237105.


Interactions of VMAT2 with CDCrel-1 and Parkin in Methamphetamine Neurotoxicity.

Chauhan H, Carruthers N, Stemmer P, Schneider B, Moszczynska A Int J Mol Sci. 2024; 25(23).

PMID: 39684782 PMC: 11642102. DOI: 10.3390/ijms252313070.


An update: epigenetic mechanisms underlying methamphetamine addiction.

Liu M, Si Z Front Cell Dev Biol. 2024; 12:1494557.

PMID: 39650725 PMC: 11621221. DOI: 10.3389/fcell.2024.1494557.


Neurotoxic Methamphetamine Doses Alter CDCel-1 Levels and Its Interaction with Vesicular Monoamine Transporter-2 in Rat Striatum.

Chauhan H, Carruthers N, Stemmer P, Schneider B, Moszczynska A bioRxiv. 2024; .

PMID: 39091864 PMC: 11291068. DOI: 10.1101/2024.07.21.604458.